OUR PIPELINE
| REGIMEN | Disease | Preclinical | Phase 1 | Phase 2 | Phase 3 | Registration Status | Learn More |
|---|---|---|---|---|---|---|---|
| Ublituximab IV: glycoengineered anti-CD20 mAb | Relapsing MS |
ULTIMATE I and II
|
APPROVED 12/28/2022 |
 |
|||
| Ublituximab IV: glycoengineered anti-CD20 mAb | Relapsing MS |
ENHANCE
|
|
||||
| Ublituximab Subcutaneous: glycoengineered anti-CD20 mAb | Relapsing MS | ||||||
| TG-1701: BTK inhibitor | B-cell disorders | ||||||
| Azer-Cel: CD19 directed allogeneic CAR-T | B-cell disorders | ||||||
The safety and efficacy of our investigational compounds and investigational uses of approved products have not been established. These products and uses have not been approved by the US Food and Drug Administration or other health authorities.
| REGIMEN | Disease | Preclinical | Phase 1 | Phase 2 | Phase 3 | Registration Status | Learn More |
|---|---|---|---|---|---|---|---|
| Ublituximab IV: glycoengineered anti-CD20 mAb | Relapsing MS |
ULTIMATE I and II
|
APPROVED 12/28/2022 |
|
|||
| Ublituximab IV: glycoengineered anti-CD20 mAb | Relapsing MS |
ENHANCE
|
|
||||
| Ublituximab Subcutaneous: glycoengineered anti-CD20 mAb | Relapsing MS | ||||||
| TG-1701: BTK inhibitor | B-cell disorders | ||||||
| Azer-Cel: CD19 directed allogeneic CAR-T | B-cell disorders | ||||||
The safety and efficacy of our investigational compounds and investigational uses of approved products have not been established. These products and uses have not been approved by the US Food and Drug Administration or other health authorities.